| Rank |
Status |
Study |
| 1 |
Not yet recruiting
|
The Effect of Hypoglycaemia on Brain Lactate Accumulation and Cerebral Blood Flow
| Conditions: |
Type 1 Diabetes Mellitus; Hypoglycemia Unawareness |
| Intervention: |
Other: glucose clamp |
| Outcome Measure: |
Brain lactate concentration |
|
| 2 |
Recruiting
|
Etiology, Assessment and Treatment of Post-gastric Bypass Severe Hypoglycemia
| Conditions: |
Obesity; Hypoglycemia; Surgery |
| Interventions: |
Dietary Supplement: Oral Glucose tolerance test (OGGT); Other: Isoglycemic intravenous glucose infusion (IIGI); Dietary Supplement: Liquid mixed meal; Drug: Octreotide; Drug: Synthetic Exendin 9-39 |
| Outcome Measures: |
Changes in biomedical markers (eg. blood glucose) in response to a liquid meal.; Continuous Glucose Monitoring as an indicator of post-gastric bypass hypoglycemia |
|
| 3 |
Recruiting
|
Outpatient Reduction of Nocturnal Hypoglycemia by Using Predictive Algorithms and Pump Suspension in Children
| Condition: |
Type 1 Diabetes |
| Intervention: |
Device: Pump suspension algorithm |
| Outcome Measures: |
Comparison of the time spent in hypoglycemia (<70 mg/dl, 3.9 mmol/L) overnight on intervention nights versus control nights, normalized to an 8-hour period.; Percentage of sensor glucose values 71 to 180 mg/dL (3.9 to 10.0 mmol/L); Proportion of nights with a sensor glucose value <=70 mg/dL (<=3.9 mmol/L); Proportion of nights with sensor glucose value <=50 mg/dL (<=2.8 mmol/L); For the nights when sensor glucose is <=60 mg/dL (<= 3.3 mmol/L), tabulation will be made as to whether blood glucose measured with study blood glucose meter; Mean home glucose meter morning glucose; Morning glucose measured with home glucose meter >=250 mg/dL (>=13.9 mmol/L); Morning blood ketones >1.0 mmol/L; Morning urine ketones >=small amount; Mean sensor glucose overnight; Percentage of sensor glucose values 71 to 180 mg/dL (3.9 to 10.0 mmol/L) overnight; Area under the curve for sensor glucose <70 mg/dL (3.9 mmol/L), 60 mg/dL (3.3 mmol/L), and 50 mg/dL (2.8 mmol/L); Area under the curve sensor glucose >180 mg/dL (10.0 mmol/L) and 240 mg/dl (13.3 mmol/L) overnight; Percent of nights with a CGM value > 250 mg/dL (13.9 mmol/L); Morning glucose measured with home glucose meter >250 mg/dL (13.9 mmol/L); Morning ketones >0.6 mmol/L; Episodes of Diabetic Ketoacidosis (DKA); Episodes of severe hypoglycemia; Change in Hemoglobin A1c; All reported adverse events; The pump settings will be analyzed for any changes from the baseline visit |
|
| 4 |
Recruiting
|
Naltrexone and Hypoglycemia in Type 1 Diabetes
| Conditions: |
Type 1 Diabetes; Hypoglycemia Unawareness |
| Intervention: |
Drug: Naltrexone |
| Outcome Measures: |
Cerebral blood flow; Rates of hypoglycemia |
|
| 5 |
Unknown †
|
Lactate and Hypoglycemia
| Condition: |
Hypoglycemia |
| Interventions: |
Drug: Lactate; Drug: Glucose |
| Outcome Measures: |
Area under the curve of the glycemia; Bispectral index variation; Maximum change in glycemia; Changes in growth hormone and cortisol; Need for glucose infusion for persistent hypoglycemia |
|
| 6 |
Not yet recruiting
|
Hypoglycemia (Low Blood Sugar) and the Heart
| Conditions: |
Hypoglycemia; Type 2 Diabetes |
| Intervention: |
|
| Outcome Measures: |
blood sugar measurement; Monitor cardiac function |
|
| 7 |
Recruiting
|
Bariatric Surgery and Reactive Hypoglycemia
| Conditions: |
Obesity With Complications; Morbid Obesity; Reactive Hypoglycemia; Bariatric Surgery |
| Interventions: |
Procedure: Gastric Bypass; Procedure: Sleeve Gastrectomy |
| Outcome Measures: |
incidence reactive hypoglycemia; insulin resistance |
|
| 8 |
Recruiting
|
Study on Lixisenatide and Counterregulation to Hypoglycemia
| Condition: |
Type 2 Diabetes |
| Intervention: |
Drug: Lixisenatide |
| Outcome Measures: |
Glucagon response to hypoglycemia; Cortisol response to hypoglycemia; Catecholamines |
|
| 9 |
Recruiting
|
Post-Gastric Bypass Hypoglycemia
| Condition: |
Hyperinsulinemic Hypoglycemia |
| Interventions: |
Other: high carbohydrate test meal; Other: high carbohydrate test meal after pre-treatment with rapid acting aspart insulin; Other: high fructose , low glucose test meal with carbohydrate and caloric content similar to the control meal |
| Outcome Measure: |
The primary study endpoint will be occurrence or not of plasma glucose < 60 mg/dL during the 4 hours after the test meal (binary endpoint). |
|
| 10 |
Recruiting
|
Hypoglycemia and Autonomic Nervous System Function
| Condition: |
Hypoglycemia |
| Interventions: |
Drug: Eplerenone; Drug: Placebo |
| Outcome Measures: |
Modified Oxford method assessment of baroreflex function; Muscle sympathetic nerve activity; Catecholamine response to lower-body negative pressure |
|
| 11 |
Recruiting
|
Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery
| Conditions: |
Hypoglycemia; Evidence of Previous Gastric Surgery |
| Intervention: |
Drug: Pramlintide |
| Outcome Measures: |
Hypoglycemia; meal hormonal responses |
|
| 12 |
Recruiting
|
Hypoglycemia in Prader-Willi Syndrome
| Conditions: |
Prader Willi Syndrome; Hypoglycemia |
| Intervention: |
Other: Infants with Prader-Willi Syndrome |
| Outcome Measure: |
Presence of hypoglycemia |
|
| 13 |
Recruiting
|
Effect of Naltrexone on Counterregulatory Mechanisms in Hypoglycemia
| Condition: |
Hypoglycemia |
| Intervention: |
Drug: Naltrexone |
| Outcome Measure: |
Hormone Levels |
|
| 14 |
Recruiting
|
Measurement of Glucose Metabolism in Humans Using Magnetic Resonance at 4 Tesla. Substudy: Hypoglycemia Unawareness
| Conditions: |
Type 1 Diabetes; Hypoglycemia Unawareness |
| Intervention: |
Drug: somatostatin |
| Outcome Measure: |
Brain glucose concentration as measured by NMR spectroscopy |
|
| 15 |
Recruiting
|
Hypoglycemia at Initiation of Pump Therapy in Children With Type 1 Diabetes
| Condition: |
Type 1 Diabetes |
| Intervention: |
Other: Observation of hypoglycemias frequency 3 days before and after pump initiation |
| Outcome Measures: |
Frequency of hypoglycemias; Frequency of hyperglycemias |
|
| 16 |
Unknown †
|
Safety and Efficacy of a Novel Glucagon Formulation in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia
| Condition: |
Hypoglycemia |
| Interventions: |
Drug: glucagon; Drug: low dose experimental formulation; Drug: high dose experimental formulation; Drug: Medium dose experimental glucagon formulation |
| Outcome Measures: |
Percentage of responders; Number of subjects with adverse events; Area under the serum concentration versus time curve (AUC) of glucagon; Peak serum concentration (Cmax)of glucagon; Peak plasma concentration (Cmax) of glucose; Area under the plasma concentration versus time curve (AUC) of glucose |
|
| 17 |
Recruiting
|
Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus
| Condition: |
Type 1 Diabetes |
| Interventions: |
Drug: Dehydroepiandrosterone; Drug: Placebo |
| Outcome Measure: |
Change in level of catecholamines in blood from baseline |
|
| 18 |
Recruiting
|
Evaluation of the Effect of Hypoglycemia With PET and a Norepinephrine Transporter Ligand
| Condition: |
Hypoglycemia |
| Intervention: |
Other: Norepinephrine Transporter (NET) ligand |
| Outcome Measures: |
norepinephrine transporter (NET) ligand concentrations at Baseline; norepinephrine transporter (NET) ligand concentrations in hyperinsulinemic-hypoglycemic Condition |
|
| 19 |
Recruiting
|
The Effects of RT-CGM on Glycemia and QoL in Patients With T1DM and IHA
| Conditions: |
Type 1 Diabetes Mellitus; Impaired Hypoglycemia Awareness; Hypoglycemia Unawareness |
| Intervention: |
Device: Real-time continuous glucose monitor |
| Outcome Measures: |
Time spent in the euglycemic range; Quality of life; Glycemia variables; Hypoglycemic episodes; Changes in hypoglycemia awareness score |
|
| 20 |
Unknown †
|
Do Sulphonylureas Preserve Cortical Function During Hypoglycaemia?
| Condition: |
Type 1 Diabetes Mellitus |
| Intervention: |
Drug: Glibenclamide |
| Outcome Measures: |
Glucose threshold for development of symptoms and cognitive impairment due to Hypoglycaemia; Improvement in counter regulatory hormone response to Hypoglycaemia |
|
